GraphLogic Installs Customized LIMS Solution for 454 Life Sciences

Branford, Connecticut - USA, March 13, 2006. GraphLogic Inc. announced today that they have completed installation of a customized sequencing LIMS for the 454 Life Sciences Sequencing Center in Branford, CT. 454 is using GraphLogic's integrated modules to manage customer projects that were sequenced with the Genome Sequencer 20™ System. The GS20™ LIMS provides a mechanism for sample tracking through all production operations including storage and inventory, sample movement through sequencing workflow and the capture of production metrics with full reporting capabilities.

"We are very pleased that 454 Life Sciences selected GraphLogic's software platform for their Sequencing Center," stated Steven Gold, founder and CEO of GraphLogic. "Our platform provides an excellent solution to the LIMS requirements associated with 454 Sequencing™ technology and other emerging technologies, which by their very nature require new and easily modifiable software."

"GraphLogic delivered a LIMS to us, uniquely customized to our processes", stated Christopher McLeod, President and CEO of 454 Life Sciences. "We have aggressive business goals, unique sequencing technology, and rigorous scientific requirements. GraphLogic's modular approach has the potential advantage of allowing independent modification to the LIMS as our business grows and changes."

GraphLogic Vice President of Life Sciences, Matthew Roth, added "we are excited to be working with 454, a company with very innovative and leading edge technology." He also stated, "Working with 454 aligns perfectly with our goal of delivering custom applications broadly throughout the life sciences. 454 continues to raise the bar, and we are confident that our platform can meet the highly unique requirements that their business demands."

About GraphLogic Inc.

GraphLogic Inc., headquartered in Branford, CT, provides a development platform and customization services, creating complex applications in less time than it takes to implement off-the-shelf software. With GraphLogic's software development platform, customers see their applications come to life, over the web, as they develop. GraphLogic custom applications are built for change, keeping pace with business requirements. Customers avoid time consuming and expensive modifications. GraphLogic customers operate in data intensive, high throughput and rapid growth production environments in the Life Sciences, Healthcare, and IT.

For more information on GraphLogic, please visit http://www.graphlogic.com.

About 454 Life Sciences Corporation

454 Life Sciences, a 66% majority-owned subsidiary of CuraGen Corporation (Nasdaq: CRGN), is commercializing next-generation instrumentation for rapidly and comprehensively conducting high-throughput nucleotide sequencing, with specific application to sequencing of whole genomes and ultra-deep sequencing of target genes. 454 Life Sciences' Genome Sequencer 20™ System enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. The hallmark of 454 Life Sciences' technology is the PicoTiterPlate™, which allows a single instrument using patented light emitting sequencing chemistries to produce over 20 million nucleotide bases per five-hour run, totaling more than 100 times the capacity of instruments using the current macro-scale technology.

The Genome Sequencer 20™ System and reagents are available exclusively from Roche Applied Sciences. For additional information on the Genome Sequencer 20™ System and reagents, please visit http://www.roche-applied-science.com/sis/sequencing/genome/. 454 Life Sciences offers sequencing services directly to customers on a fee for service basis at their state-of-the-art Sequencing Center.

For additional information on 454 Life Sciences, please visit http://www.454.com.

Press Contact:

June Gold
GraphLogic Inc.
388 East Main St., Branford, CT 06405
203-488-1922 x 103
press@graphlogic.com